In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024
The entry of 11 novel therapies into the non-small-cell lung cancer (NSCLC) market will drive the market's growth from $5.4 billion in 2014 to $12.7 billion in 2024, according to a new report. 28 October 2015
Better-than-expected revenues from cancer therapy Opdivo (nivolumab) were a major driver behind Bristol-Myers Squibb beating third quarter profit estimates. 27 October 2015
Anglo-Swedish pharma major AstraZeneca’s drug to treat women with genetic cancers can also benefit men with advanced prostate cancer, according to a new research. 26 October 2015
Stock market research firm Goldman Small Cap Research has published a new sponsored research article on US clinical stage biotech firm PharmaCyte Biotech’s investigational pancreatic cancer treatment. 26 October 2015
The US Food and Drug Administration has issued a complete response letter to Spectrum Pharmaceuticals on Evomela (melphalan) to treat multiple myeloma. 26 October 2015
Danish biotech company Genmab said it is set to receive $3 million in milestone payment from Janssen Biotech, a unit of US health care giant Johnson & Johnson, following a pre-clinical advancement for its DuoBody technology platform. 26 October 2015
The European Medicines Agency’s scientific committee on Friday recommended authorizing Imlygic (talimogene laherparepvec) for the treatment of adults with melanoma. 24 October 2015
The US Food and Drug Administration on Friday approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS) - liposarcoma (LPS) and leiomyosarcoma (LMS) - that cannot be removed by surgery (unresectable) or is advanced (metastatic). 24 October 2015
US health care giant Johnson & Johnson is set to launch its drug to treat multiple myeloma in 2016, pending regulatory approvals, Peter Lebowitz, head of global oncology, Janssen Pharmaceutical Companies of Johnson & Johnson, told The Pharma Letter in an interview at a London event. 23 October 2015
Hutchison China MediTech on Friday said its drug and research arm, Hutchison MediPharma, is set to receive a $10 million milestone payment, in the fourth quarter of 2015, from its partner US drug major Eli Lilly and Co. 23 October 2015
The US Food and Drug Administration has approved Onivyde (irinotecan liposome injection) from Merrimack, in combination with fluorouracil and leucovorin in advanced pancreatic adenocarcinoma previously treated with gemcitabine-based chemotherapy. 23 October 2015
USA-based Viropro says it has signed a non-binding Letter of Intent for the acquisition of NovaRx, a San Diego-based pioneer in immuno-oncology. 23 October 2015
A clinical trial has been launched in the UK to establish whether daily aspirin can stop or delay the recurrence of cancers that were previously caught and treated at an early stage. 23 October 2015
Anglo-Swedish drug major AstraZeneca and Eli Lilly have announced an extension to their current immuno-oncology collaboration, researching novel combinations for solid tumors. 22 October 2015
EMD Millipore has entered into a strategic alliance with Turgut Ilac, a leading biosimilars company based in Turkey and will provide their Provantage End-to-End services for development and manufacturing of biologics. 22 October 2015
Switzerland’s Roche has posted sales figures for the first nine months of 2015. Group sales for the period of 35.5 billion Swiss francs ($36.98 billion) increased 6% at constant exchange rates and 2% in francs. 22 October 2015
US cancer drug developer Kite Pharma has entered into an exclusive, worldwide license with the US National Institutes of Health (NIH) for intellectual property. 22 October 2015
The treatment market for multiple myeloma across the Asia-Pacific (APAC) countries of China, India, Japan, and Australia will rise in value from $1.7 billion in 2014 to $2.8 billion by 2021, representing a compound annual growth rate (CAGR) of 7.4%, new research forecasts. 21 October 2015
Novartis this morning announced that it is broadening its portfolio of cancer immunotherapies with the acquisition of Admune Therapeutics and licensing agreements with Palobiofarma and XOMA Corp. 21 October 2015